Karyopharm announces strategic financing

US cancer focused pharma Karyopharm Therapeutics (Nasdaq: KPTI) saw its shares slide 12.4% to $5.06 by late morning, after it disclosed a comprehensive financing and capital structure transactions expected to provide the company with $100 million of financial flexibility and additional capital, extending the company’s cash runway into the second quarter of 2026 based on the company’s current operating plans.

“Following the recent completion of enrollment of our Phase III SENTRY trial in myelofibrosis, we are excited to announce this strategic financing which is expected to provide us with the resources needed to deliver top-line data from this pivotal trial,” said Richard Paulson, president and chief executive of Karyopharm, adding: “We believe that selinexor plus ruxolitinib has the potential to be the first combination therapy approved for the treatment of myelofibrosis. By combining selinexor with the current standard of care, we have the potential to redefine the way people living with myelofibrosis are treated."

Each of the financing and capital structure transactions is expected to close on or around October 10, 2025 (Closing Date), subject to the satisfaction of customary closing conditions. The company’s existing senior lenders have agreed to multi-faceted financing transactions with the following key components: